Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier

Gregory W. Randolph,1,2 Julie Ann Sosa,3 Yangyang Hao,4 Trevor E. Angell,5 David C. Shonka, Jr.,6 Virginia A. LiVolsi,7 Paul W. Ladenson,8 Thomas C. Blevins,9 Quan-Yang Duh,10 Ronald Ghossein,11 Mack Harrell,12 Kepal Narendra Patel,13 Michael H. Shanik,14 S. Thomas Traweek,15 P. Sean Walsh,4 Michael W. Yeh,16 Amr H. Abdelhamid Ahmed,1 Allen S. Ho,17 Richard J. Wong,18 Joshua P. Klopper,19 Jing Huang,4 Giulia C. Kennedy,4,19 Richard T. Kloos,19 and Peter M. Sadow20,21

Background: Cytopathological evaluation of thyroid fine-needle aspiration biopsy (FNAB) specimens can fail to raise preoperative suspicion of medullary thyroid carcinoma (MTC). The Afirma RNA-sequencing MTC classifier identifies MTC among FNA samples that are cytologically indeterminate, suspicious, or malignant (Bethesda categories III–VI). In this study we report the development and clinical performance of this MTC classifier.

Methods: Algorithm training was performed with a set of 483 FNAB specimens (21 MTC and 462 non-MTC). A support vector machine classifier was developed using 108 differentially expressed genes, which includes the 5 genes in the prior Afirma microarray-based MTC cassette.

Results: The final MTC classifier was blindly tested on 211 preoperative FNAB specimens with subsequent surgical pathology, including 21 MTC and 190 non-MTC specimens from benign and malignant thyroid nodules independent from those used in training. The classifier had 100% sensitivity (21/21 MTC FNAB specimens correctly called positive; 95% confidence interval [CI] = 83.9–100%) and 100% specificity (190/190 non-MTC specimens correctly called negative).
FNAs correctly called negative; CI = 98.1–100%). All positive samples had pathological confirmation of MTC, while all negative samples were negative for MTC on surgical pathology.

**Conclusions:** The RNA-sequencing MTC classifier accurately identified MTC from preoperative thyroid nodule FNAB specimens in an independent validation cohort. This identification may facilitate an MTC-specific preoperative evaluation and resulting treatment.

**Keywords:** indeterminate cytology, machine learning, medullary thyroid cancer, molecular diagnostics, molecular testing, thyroid nodule

**Introduction**

**M**edullary thyroid carcinoma (MTC) comprises 1–2% of all thyroid cancer cases, yet it is more likely to cause death than the more common types of thyroid cancer.1,2 Ten-year disease-specific survival when disease is confined to the thyroid spreads regionally through extrathyroidal extension or cervical lymph node metastases, or with distant disease is 96%, 77%, and 44%, respectively.2 Cytopathological evaluation of thyroid fine-needle aspiration biopsy (FNAB) specimens can fail to raise preoperative suspicion of MTC, missing more than one-half of these important malignancies.3,4

In a multicenter international study, Essig et al5 reported that among 245 surgically confirmed MTC cases, only 44% were diagnosed as MTC by cytology and another 2% as possible MTC.5 Sixteen percent were cytologically diagnosed as malignant or suspicious for malignancy, but without the specific suggestion of MTC. Twenty-six percent had cytological diagnoses that approximated Bethesda category III or IV classification. When MTC is not specifically identified preoperatively, these patients are at risk of receiving an insufficient preoperative evaluation and initial thyroid surgery that is not consistent with accepted guidelines.1 Surgical treatment discordant with guideline recommendations has been associated with compromised disease-specific survival.6

Early MTC detection and treatment are associated with improved patient outcomes. In a national study from Ireland, median survival was 6.3 years, with better outcomes predicted by younger patient age and lower tumor stage.7 In another European series of ~900 MTC patients, calcitonin and carcinoembryonic antigen (CEA) normalized in only 43% of surgical patients,8 with independent predictors of survival also pointing to younger patient age and lower tumor stage.8 Others have reported that the response to initial surgical therapy is a better predictor of long-term prognosis compared with TNM stage alone,9 but earlier disease identification is shared among patients with more favorable surgical responses and lower TNM stages.

Tuttle and Ganly reported that predictors of excellent response to therapy included lower preoperative calcitonin and CEA levels, smaller primary tumor size, less extensive nodal disease, and early stage disease at presentation.9 Surgery when disease is confined to the thyroid gland optimizes the chance for cure. Similar to findings from the United States,9 a French experience reported the 10-year survival rate was 96% for disease confined to the thyroid, falling to 75% with nodal involvement and 40% with distant metastasis.10 While more effective therapies for metastatic disease are clearly needed, optimizing the initial surgical interaction is also important for long-term survival in MTC.

Basal serum calcitonin screening for MTC in thyroid nodule patients is somewhat controversial, as few patients have definitively high values (>100 ng/L), and diagnostic confusion is created among the greater number with marginally abnormal values of 10–100 ng/L.11 For example, in a type 2 diabetes population with high cardiovascular risk, 10.8% had serum calcitonin values >10 ng/L, and 2.6% had values >20 ng/L.12 A better diagnostic test would be both highly sensitive and highly specific. The utility of calcitonin secretagogues toward resolving borderline basal serum calcitonin values is uncertain,1 and pentagastrin is largely unavailable.

A microarray-based Afirma MTC classifier was previously developed and validated for use among cytologically Bethesda categories III–VI nodules to specifically identify MTC.11 When Afirma migrated to an RNA-sequencing platform,13 a new RNA-sequencing-based MTC classifier was developed using machine learning. Here we report the development and clinical validation of this new classifier.

**Materials and Methods**

**Feature selection**

Four hundred eighty-three thyroid nodule FNAB specimens (including 21 from MTC) and 97 independent surgical tissue samples from tumors (including 21 from MTC) were used for feature (gene) selection. The surgical tissues were included to select genes that were differentially expressed (DE) between MTC and non-MTC (neoplasm or mass that was not MTC) for both FNAB and surgical tissue samples to avoid selecting DE genes irrelevant to the MTC phenotype (Fig. 1).

Eight candidate feature sets were constructed using various rules to reduce the number of included DE genes: (candidate feature set 1) DE genes with adjusted p-value <1e-6, (candidate feature set 2) DE genes with adjusted p-value <1e-6 and log2-fold change >6, (candidate feature sets 3–5) hierarchical clustering on DE genes (adjusted p-value <0.01), then select one, 20% or 50% genes from each cluster, (candidate feature sets 6–8) cluster genes by recursive partition using HOPACH14 then select 10%, 20%, or 50% genes from each cluster. The 5 genes in the original Afirma microarray-based MTC cassette and 29 literature-derived genes of potential interest were included (Supplementary Table S1) in each of the 8 candidate feature sets.

**Classifier training**

The 483 thyroid FNAB specimens already mentioned were used for the RNA-sequencing MTC classifier training to generate a result of positive or negative for MTC (Fig. 2). Among the specimens were 21 FNAB specimens from surgically confirmed MTC (5 Bethesda category III, 6 Bethesda...
Among the 21 MTC FNAB specimens used for validation testing, all had a diagnosis of MTC by surgical pathology. All reference labels were assigned and locked before the development of the Afirma RNA-sequencing MTC classifier.

**Independent classifier validation**

The final RNA-sequencing MTC classifier was blindly tested on 211 retrospective FNAB samples that were independent from those used in classifier training and that included 21 MTC (Table 1) and 190 non-MTC samples from benign and malignant thyroid samples. In total, 191 of these samples were the Bethesda categories III/IV Afirma Gene Sequencing Classifier validation cohort that included 1 surgical pathology confirmed MTC (Table 1 sample 1) and 190 surgical pathology confirmed non-MTC samples (surgical histologies listed in Table 5 of Patel et al\(^1\)).

These 191 samples were originally collected under a prospective multicenter blinded sample collection protocol for the Afirma Gene Expression Classifier (GEC) validation.\(^1\) The 190 non-MTC FNAB samples came from 182 patients with a mean age of 52 years (range 22–85); 77% were female, with a mean nodule size of 2.6 cm (range 1.0–9.1). The remaining 20 MTC samples included the 1 remaining MTC sample from the Afirma GEC validation cohort\(^1\) (Table 1 sample 2) and 19 histology-confirmed MTC samples identified as positive by the Afirma microarray-based MTC classifier by June 2013.

**Statistics**

Statistical analyses were performed using R statistical software version 3.2.3. The exact binomial test was used to calculate 95% confidence intervals (CIs). One-sample proportion test power analysis was performed using R package pwr. DE analysis was conducted using DESeq2,\(^1\) and the p-values were multiple-hypothesis corrected using the Benjamini–Hochberg procedure.\(^1\) We evaluated test performance using sensitivity and specificity. For sample size considerations based on a one-sample proportion test power analysis, the null hypothesis of a sensitivity of 90% could be rejected with >90% power at the 0.05 significance level if the classifier could demonstrate 100% sensitivity.

**Institutional review board approval**

Specimen collection and research were performed with patient consent or IRB waiver as approved by institution-specific institutional review boards as well as by Liberty IRB (DeLand, Florida; now Chesapeake IRB) and Copernicus Group Independent Review Board (Cary, NC).

**Results**

**Classifier selection**

All trained classifiers showed 100% sensitivity and specificity on the training set. The following criteria were used to select the single most robust model (classifier): (1) greatest distance between minimum MTC and maximum non-MTC classifier logit scores, (2) smallest logit score variability among controls that were sequenced repeatedly together with training samples, (3) highest logit score correlation with Afirma microarray-based MTC cassette, and (4) smallest number of genes in the model.
A SVM classifier using candidate feature set 2 (gene inclusion required adjusted p-value <1e-6 and log2-fold change >6 for both MTC FNAB specimens and tissues compared with those without MTC) was selected as the final model for subsequent independent validation. This locked classifier includes 108 genes (Supplementary Table S1).

Independent validation

The final RNA-sequencing MTC classifier was blindly tested on 211 independent preoperative FNAB specimens whose surgical pathology included 21 MTC and 190 non-MTC specimens from benign and malignant thyroid samples.
The RNA-sequencing MTC classifier had 100% sensitivity (21/21 MTC FNAB specimens correctly called positive; CI = 83.9–100%) and 100% specificity (190/190 non-MTC FNAB specimens correctly called negative; CI = 98.1–100%). All positive samples had surgical confirmation of MTC, while all negative samples were negative for MTC on surgical pathology. The age range of patients with MTC was 18–78 years, 81% were female, their largest tumor dimension on ultrasound range was 0.7–5.3 cm, preoperative basal serum calcitonin range was 8–10,702 ng/L, FNAB cytology was Bethesda category III (38%), IV (29%), or V (33%), while 53% were stage I and 47% were stage II and higher (Table 1).

All positive samples had surgical confirmation of MTC, while all negative samples were negative for MTC on surgical pathology. The age range of patients with MTC was 18–78 years, 81% were female, their largest tumor dimension on ultrasound range was 0.7–5.3 cm, preoperative basal serum calcitonin range was 8–10,702 ng/L, FNAB cytology was Bethesda category III (38%), IV (29%), or V (33%), while 53% were stage I and 47% were stage II and higher (Table 1).

Discussion

In this study we report the development and independently blinded clinical validation of the Afirma RNA-sequencing MTC classifier that has demonstrated high sensitivity and specificity. All positive samples had surgical confirmation of MTC, while all negative samples were negative for MTC on surgical pathology. Throughout training and validation, highly accurate performance was seen among cytologically Bethesda categories III–VI FNA samples.

All MTCs were correctly identified in both cross-validation of the training cohort and the independent validation cohort. MTCs in the training cohort were 24% Bethesda category III, 29% Bethesda category IV, 29% Bethesda category V, and 19% Bethesda category VI. MTCs in the validation cohort were 38% Bethesda category III, 29% Bethesda category IV, and 33% Bethesda category V. The MTC classifier correctly identified MTCs as small as 7 mm follicular carcinomas or well-differentiated carcinoma not otherwise specified, and 1 poorly differentiated thyroid carcinoma.

### Table 1. Demographics of the 21 Medullary Thyroid Carcinoma Nodules in the Clinical Validation Cohort

| MTC FNA Sample | Patient age (years) | Sex | Thyroid nodule location | Nodule largest ultrasound dimension (cm) | Cytology Bethesda category | Preoperative basal serum calcitonin (ng/L) | TNM |
|----------------|---------------------|-----|------------------------|------------------------------------------|---------------------------|--------------------------------------------|-----|
| 1              | 43                  | Female | Right              | 2.9                                      | IV                        | NA                                         | T1bNXMX |
| 2              | 66                  | Female | Right              | 1.5                                      | V                         | NA                                         | T1bN0MX |
| 3              | 49                  | Female | Right              | 1.0                                      | III                       | 1200                                       | NA  |
| 4              | 18                  | Female | Left               | 1.7                                      | V                         | 18                                         | T1bN0MX |
| 5              | 78                  | Female | Right              | 4.0                                      | III                       | 10,702                                     | T2N0MX |
| 6              | 35                  | Female | Left               | 2.5                                      | III                       | 1095                                       | T2N1bMX |
| 7              | 52                  | Female | Left               | 2.1                                      | V                         | 6912                                       | T2N1bMX |
| 8              | 52                  | Male   | Left               | 5.1                                      | V                         | 6149                                       | T3aN1bMX |
| 9              | 62                  | Female | Left               | 1.5                                      | III                       | 122                                        | T1bNXMX |
| 10             | 55                  | Male   | Right              | 5.3                                      | IV                        | 6866                                       | T3aN0MX |
| 11             | 73                  | Female | Right              | 4.0                                      | III                       | NA                                         | NA  |
| 12             | 44                  | Female | Right              | 0.7                                      | IV                        | 8                                          | T1aN1aMX |
| 13             | 35                  | Female | Right              | 1.0                                      | V                         | 34                                         | T1aN1MX |
| 14             | 69                  | Female | Right              | 1.6                                      | IV                        | 111                                        | T1bNXMX |
| 15             | 58                  | Female | Right              | NA                                       | III                       | 495                                        | T1bN0MX |
| 16             | 25                  | Female | Left               | 2.1                                      | V                         | 158                                        | T2NXXM |
| 17             | 49                  | Female | Left               | 1.2                                      | III                       | 61                                         | T1aN0MX |
| 18             | 48                  | Female | Right              | 1.7                                      | III                       | 4000                                       | T2N1MX |
| 19             | 71                  | Female | Left               | 0.8                                      | IV                        | NA                                         | T1aNXMX |
| 20             | 50                  | Male   | Left               | 1.0                                      | IV                        | 92                                         | T1aNXMX |
| 21             | 65                  | Female | Left               | 1.4                                      | V                         | 157                                        | T1bN0MX |

| Median (range) or percent | 52 (18–78) | 81% Female | 57% Right | 2.1 (0.7–5.3) | 38% III | 29% IV | 33% V | 158 (8–10,702) | Stage I: 53% | Stage II: 16% | Stage III: 16% | Stage IVA: 16% |

All had surgical pathology confirmed MTC. Demographics of 190 non-MTC nodules in the clinical validation cohort are reported in the Materials and Methods section. Cancer staging per AJCC 8th edition. Summary statistics exclude missing data.

Tumor size at surgical pathology was 1.8 cm.

Stage was calculated by assuming that NX and MX are NO and MO, respectively. N1 unspecified (i.e., N1a vs. N1b) was assumed to be N1a.

AJCC, American Joint Committee on Cancer; FNA, fine-needle aspiration; MTC, medullary thyroid carcinoma; NA, calcitonin not available, or accessible medical records are insufficiently detailed for accurate TNM classification.
and in patients as young as 18 years old, even when baseline serum calcitonin was <20 ng/L (Table 1).

Separate from the clinical validation performance reported here, analytical validation of the Afirma RNA-sequencing MTC classifier was previously published.\(^\text{19}\) This included measures of accuracy between different laboratories, precision, analytical sensitivity, and analytical specificity. The positive signal in an MTC sample was shown to tolerate up to 75% dilution by benign RNA and still yield a positive MTC classifier result. Beyond the analytical and clinical validation data, future investigations should evaluate cost-effectiveness.

The indication for Afirma RNA-sequencing MTC classifier consideration is among cytologically indeterminate (Bethesda categories III/IV), suspicious (Bethesda category V), or malignant (Bethesda category VI) thyroid nodules that lack a definitive diagnosis of MTC when such a diagnosis would alter their treatment. While MTC is not typically suspected among FNAB samples read as cytologically indeterminate, so too can MTC be identified among cytologically malignant samples that are not specifically identified as MTC.\(^\text{3,5,17,20}\) Conversely, some FNAB specimens cytologically suspected of MTC are found to have alternative diagnoses upon surgical resection.\(^\text{11}\)

Without the specific identification of MTC, MTC patients are unlikely to receive the appropriate evaluation, testing, staging, and treatment that they would otherwise receive according to management guidelines.\(^\text{1,21}\) The preoperative evaluation includes germline \(\text{RET}\) mutation testing and consideration and treatment of MEN2-associated pheochromocytoma if present.\(^\text{1}\) Thyroid surgery on an MEN2 patient with an untreated pheochromocytoma can result in perioperative morbidity and death.\(^\text{22}\) The minimal thyroid surgery recommended for MTC that presents as a thyroid nodule (≥1 cm) is total thyroidectomy and prophylactic central neck dissection.\(^\text{1,21}\) This is a more extensive surgery than is recommended for cytologically indeterminate thyroid nodules or most differentiated thyroid carcinomas that are confined to the thyroid.\(^\text{23}\)

Failure to diagnose MTC preoperatively may result in delayed and insufficient initial treatment and lead to subsequent surgeries. This may partly explain why 40% or more of initial surgical treatments for MTC patients are less extensive than advised by guideline recommendations.\(^\text{6,24,25}\) Kuo et al\(^\text{25}\) reported that lymph node dissection was associated with decreased MTC recurrence leading to reoperation (hazard ratio, 0.53; CI = 0.30–0.93) according to data from the California Cancer Registry and the Office of Statewide Health Planning and Development.\(^\text{25}\)

Panigrahi et al analyzed Surveillance, Epidemiology, and End Results (SEER) data and reported that disease-specific survival was shorter in patients who did not receive appropriate surgery according to guidelines.\(^\text{6}\) Randle et al reported improved surgical approach and survival in the most recent decade according to SEER data, yet nearly one-quarter of MTC patients remain insufficiently treated.\(^\text{2}\) They speculated that limitations in the preoperative diagnosis of MTC by FNAB-mediated cytology evaluation may have contributed to this treatment insufficiency. It is possible that stronger clinical practice guideline recognition and endorsement of preoperative MTC molecular diagnostic testing among Bethesda categories III–VI nodules may improve patient outcomes.

A limitation of this study is the relatively small number of MTC cases included in the cross-validation cohort and the independent and blinded validation cohort. MTC has a low incidence among thyroid cancers and is rare by incidence in the general population,\(^\text{7}\) which makes assembling large cohorts of preoperative FNAB specimens from them difficult. Still, the number of MTCs included here is the largest independent validation cohort among available molecular diagnostic tests that specifically identify MTC. In the genomic space, the molecular patten of MTC is very distinct from non-MTC samples. Given this, it seems unlikely that a greater number of MTC samples in a validation cohort would significantly alter test performance.

In real-world clinical experience, publications with Afirma RNA-sequencing MTC classifier testing conducted independently from Veracyte, there have been no false negative or false positive results reported among >2100 thyroid nodules.\(^\text{26–39}\) This robust finding may also mitigate the potential limitation of some authors having a multiplicity of interests. Statistical analyses were performed by Veracyte. Reference diagnoses were assigned by surgical pathologists not employed by Veracyte. Most authors have no Veracyte financial interests. Another limitation of this study is the lack of Non-Invasive Follicular Thyroid neoplasm with Papillary-like nuclear features (NIFTP) in the validation cohort.

This tumor type nomenclature came into existence only after this non-MTC validation cohort was collected and their surgical pathology diagnoses assigned.\(^\text{13,15}\) If any NIFTP exist in this cohort, they resulted negative with the Afirma RNA-sequencing MTC classifier. Only 26 of the 42 MTC cases with FNAB samples used here in training or validation have known germline \(\text{RET}\) protooncogene results.\(^\text{40}\) The MTC classifier performance was not studied in conjunction with calcitonin measurements in this study.

**Conclusion**

We report the development and blinded independent clinical validation of the Afirma RNA-sequencing MTC classifier. All positive samples had surgical pathology confirmation of MTC, while all negative samples were negative for MTC postoperatively. This test facilitates the preoperative diagnosis of MTC to enable appropriate initial treatment of MTC patients with Bethesda categories III–VI FNA cytology.

**Authors’ Contributions**

The authors confirm contribution to the article as follows: study conception and design: Y.H., P.S.W., J.H., G.C.K., and R.T.K.; data collection: Y.H., P.S.W., J.H., G.C.K., and R.T.K.; statistical analysis: Y.H. and J.H.; analysis and interpretation of results: G.W.R., P.M.S., T.E.A., D.C.S., V.A.L., P.W.L., T.C.B., Q.D., R.A.G., R.M.H., K.N.P., M.H.S., S.T.T., M.W.Y., A.H.A.A., A.S.H., R.J.W., J.A.S.,
Y.H., P.S.W., J.P.K., J.H., G.C.K., and R.T.K.; draft article preparation: G.W.R. and R.T.K. All authors reviewed the results, edited, and approved the final version of the article.

Acknowledgments

G.W.R. acknowledges the ongoing support of John and Claire Bertucci and Mike and Eliz Ruane for his research efforts. P.M.S. is supported in part by the National Cancer Institute of the National Institutes of Health 5P01CA240239-03. Part of this research was previously presented at the 87th Annual Meeting of the American Thyroid Association October 18–22, 2017.

Author Disclosure Statement

G.W.R. has received a research grant (no personal fees) from Eisai. G.W.R. is the president of the International Thyroid Oncology Group (ITOG) and the World Congress on Thyroid Cancer (WCTC) and is chair of the Administrative Division of the American Head and Neck Society (AHNS). Y.H., P.S.W., J.P.K., J.H., G.C.K., and R.T.K. are Veracyte employees and equity owners. P.W.L. is an advisor to Veracyte. J.A.S. is a member of the data monitoring committee of the Medullary Thyroid Cancer Consortium Registry supported by GlaxoSmithKline, Novo Nordisk, Astra Zeneca, and Eli Lilly and receives institutional research funding from Exelixis and Eli Lilly. All other authors report no conflict of interest.

Funding Information

This study was funded by Veracyte. Non-Veracyte authors received no financial support for the research, authorship, or publication of this article.

Supplementary Material

Supplementary Table S1

References

1. Wells SA, Jr., Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25(6):567–610; doi:10.1089/thy.2014.0335.
2. Randle RW, Balentine CJ, Leversion GE, et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery 2017;161(1):137–146; doi:10.1016/j.surg.2016.04.053.
3. Workman AD, Soylu S, Kamani D, et al. Limitations of preoperative cytology for medullary thyroid cancer: Proposal for improved preoperative diagnosis for optimal initial medullary thyroid carcinoma specific surgery. Head Neck 2021;43(3):920–927; doi: 10.1002/hed.26550.
4. Trimboli P, Treglia G, Guidobaldi L, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: A meta-analysis. Clin Endocrinol (Oxf) 2015;82(2):280–285; doi: 10.1111/cen.12563.
5. Essig GF, Jr., Porter K, Schneider D, et al. Fine needle aspiration and medullary thyroid carcinoma: The risk of inadequate preoperative evaluation and initial surgery when relying upon FNAB cytology alone. Endocr Pract 2013; 19(6):920–927; doi:10.4158/EP13143.OR.
6. Panigrahi B, Roman SA, Sosa JA. Medullary thyroid cancer: Are practice patterns in the United States discordant from American Thyroid Association guidelines? Ann Surg Oncol 2010;17(6):1490–1498; doi:10.1245/s10434-010-1017-0.
7. Lennon P, Deady S, White N, et al. Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry. Ir J Med Sci 2017;186(1):89–95; doi:10.1007/s11845-016-1455-1.
8. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: Results in 899 patients. The GETC Study Group. Groupe d’étude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 1998;48(3):265–273; doi:10.1046/j.1365-2265.1998.00392.x.
9. Tuttle RM, Ganly I. Risk stratification in medullary thyroid cancer: Moving beyond static anatomic staging. Oral Oncol 2013;49(7):695–701; doi:10.1016/j.oraloncology.2013.03.443.
10. Scollo C, Baudin E, Travagl JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003;88(5):2070–2075; doi:10.1210/jc.2002-021713.
11. Kloos RT, Monroe RJ, Traweek ST, et al. A genomic alternative to identify medullary thyroid cancer preoperatively in thyroid nodules with indeterminate cytology. Thyroid 2016;26(6):785–793; doi:10.1089/thy.2016.0001.
12. Daniels GH, Hegedus L, Marso SP, et al. LEADER 2: Baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: Preliminary observations. Diabetes Obes Metab 2015;17(5):477–486; doi:10.1111/dom.12444.
13. Patel KN, Angell TE, Babiarz J, et al. Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules. JAMA Surg 2018;153(9):817–824; doi:10.1001/jamasurg.2018.1153.
14. van der Laan MJ, Pollard KS. A new algorithm for hybrid hierarchical clustering with visualization and the bootstrap. J Stat Plan Inference 2003;117(2):275–303; doi:10.1016/s0378-3758(02)00388-9.
15. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012;367(8):705–715; doi:10.1056/NEJMoa1203208.
16. Amin MB, American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual. American Joint Committee on Cancer, Springer: Chicago IL; 2017.
17. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014;15(12):550; doi:10.1186/s13059-014-0550-8.
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Stat Soc Ser B (Methodological) 1995;57(1):289–300; http://www.jstor.org/stable/2346101
19. Hao Y, Choi Y, Babiarz JE, et al. Analytical verification performance of afirma genomic sequencing classifier in the diagnosis of cytologically indeterminate thyroid nodules. Front Endocrinol (Lausanne) 2019;10(438):1–9; doi:10.3389/fendo.2019.00438.
20. Wirth LJ, Ross DS, Randolph GW, et al. Case records of the Massachusetts General Hospital. Case 5-2013. A 52-year-old woman with a mass in the thyroid. N Engl J Med 2013;368(7):664–673; doi:10.1056/NEJMcp1210080.
21. NCCN Clinical Practice Guidelines in Oncology. Thyroid Carcinoma. Version 3.2021; 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf [Last Accessed: March 18].
22. Wozniakowska W, Maka B, Laskowska M, et al. [Problems associated with general anesthesia in patients with thyroid cancer]. Wiad Lek 2001;54(Suppl. 1):234–240.
23. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1–133; doi:10.1089/thy.2015.0020.
24. Esfandiari NH, Hughes DT, Yin H, et al. The effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer. J Clin Endocrinol Metab 2014;99(2):448–454; doi:10.1210/jc.2013-2942.
25. Kuo EJ, Sho S, Li N, et al. Risk factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma. JAMA Surg 2018;153(1):52–59; doi:10.1001/jamasurg.2017.3555.
26. Harrell RM, Eyerly-Webb SA, Golding AC, et al. Statistical comparison of afirma Gsc and afirma Gec outcomes in a community endocrine surgical practice: Early findings. Endocr Pract 2019;25(2):161–164; doi:10.4158/EP-2018-0395.
27. Angell TE, Heller HT, Cibas ES, et al. Independent comparison of the afirma genomic sequencing classifier and gene expression classifier for cytologically indeterminate thyroid nodules. Thyroid 2019;29(5):650–656; doi: 10.1089/thy.2018.0726.
28. Endo M, Nabhan F, Porter K, et al. Afirma gene sequencing classifier compared with gene expression classifier in indeterminate thyroid nodules. Thyroid 2019;29(8):1115–1124; doi:10.1089/thy.2018.0733.
29. Wei S, Veloski C, Sharda P, et al. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience. Cancer Cytopathol 2019;127(11):720–724; doi:10.1002/cncr.22188.
30. San Martin VT, Lawrence L, Bena J, et al. Real-world comparison of afirma GEC and GSC for the assessment of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 2020;105(3):e428–e435; doi:10.1210/clinem/dgj099.
31. Andrioli M, Carocci S, Alessandri S, et al. Testing for Afirma in thyroid nodules with high-risk indeterminate cytology (TIK3B): First Italian experience. Endocr Pathol 2020;31(1):46–51; doi:10.1007/s12022-020-09604-7.
32. Endo M, Porter K, Long C, et al. Features of cytologically indeterminate molecularly benign nodules treated with surgery. J Clin Endocrinol Metab 2020;105(11):e3971–e3980; doi:10.1210/clinem/dgaa506.
33. Geng Y, Aguilar-Jakthong JS, Moatamed NA. Comparison of Afirma gene expression classifier with gene sequencing classifier in indeterminate thyroid nodules: A single-institutional experience. Cytopathology 2021;32(2):187–191; doi:10.1111/cyt.12920.
34. Livhits MJ, Zhu CY, Kuo EJ, et al. Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: A randomized clinical trial. JAMA Oncol 2021;7(1):70–77; doi:10.1001/jamaoncol.2020.5935.
35. Gortakowski M, Feghali K, Osakwe I. Single institution experience with Afirma and Thyroseq testing in indeterminate thyroid nodules. Thyroid 2021;31(9):1376–1382; doi:10.1089/thy.2020.0801.
36. Zhang L, Smola B, Lew M, et al. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience. Diagn Cytopathol 2021;49(8):921–927; doi:10.1002/dc.24765.
37. Yang Z, Zhang T, Layfield L, et al. Performance of Afirma gene sequencing classifier versus gene expression classifier in thyroid nodules with indeterminate cytology. J Am Soc Cytopathol 2022;11(2):74–78; doi:10.1016/j.jasc.2021.07.002.
38. Babazadeh NT, Sinclair TJ, Krishnamurthy V, et al. Thyroid nodule molecular profiling: The clinical utility of Afirma Xpression Atlas for nodules with Afirma Genomic Sequencing Classifier-suspicious results. Surgery 2022; 171(1):155–159; doi:10.1016/j.surg.2021.08.058.
39. Polavarapu P, Fingeret A, Yuil-Valdes A, et al. Comparison of Afirma GEC and GSC to nodules without molecular testing in cytologically indeterminate thyroid nodules. J Endocrinol Soc 2021;5(11):bvab148; doi:10.1210/jends/bvab148.
40. Hu MI, Waguespack SG, Dosiou C, et al. Afirma genomic sequencing classifier and Xpression atlas molecular findings in consecutive Bethesda III-VI thyroid nodules. J Clin Endocrinol Metab 2021;106(8):2198–2207; doi:10.1210/clinem/dgab304.
41. Randolph G, Angell TE, Babiarz J, et al. Clinical validation of the Afirma Genomic Sequencing Classifier for medullary thyroid cancer (Clinical Oral Abstract 29). Thyroid 2017; 27(S1):A105; doi:10.1089/thy.2017.29046.abstracts.

Address correspondence to:
Peter M. Sadow, MD, PhD
Departments of Pathology
Massachusetts General Hospital
and Harvard Medical School
Boston, MA 02114
USA
E-mail: psadow@mgh.harvard.edu